The treatment of fungal infections is limited by lack of innovative therapies due to the low rate of antifungal and antibiotic drug development and costly clinical trials. Thus, the government had changed the regulations and started to support the research & development of antifungal drugs. The new regulatory norms have included priority review and regulatory guidance enabling smaller clinical trials. The Generating Antibiotics Incentives Now ... Read more
The treatment of fungal infections is limited by lack of innovative therapies due to the low rate of antifungal and antibiotic drug development and costly clinical trials. Thus, the government had changed the regulations and started to support the research & development of antifungal drugs. The new regulatory norms have included priority review and regulatory guidance enabling smaller clinical trials. The Generating Antibiotics Incentives Now ... Read more
